GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Capital Expenditure

NAMS (NewAmsterdam Pharma Co NV) Capital Expenditure : $-0.67 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

NewAmsterdam Pharma Co NV's cash flow for capital expenditures for the three months ended in Dec. 2024 was $-0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.67 Mil.

NewAmsterdam Pharma Co NV Capital Expenditure Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Capital Expenditure Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
-0.02 -0.02 -0.22 -0.02 -0.67

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.39 -0.21 -0.08 -

NewAmsterdam Pharma Co NV Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewAmsterdam Pharma Co NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Capital Expenditure
Comparable Companies
RXRX APGE MLTX MIRM VCEL BEAM EWTX FOLD XENE DNLI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
KH6:Germany
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
Website
https://www.newamsterdampharma.com
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.